News

Kanagawa, Japan, 18 September 2023 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ryoma Hara, Ph.D., Principal Scientist of FIMECS, will make a presentation at the Protein Degradation & Targeting Undruggables Europe 2023 (19-20 September 2023 in Basel, Switzerland). Title is “Achieving Efficiency in Degrader Discovery and Expansion of the E3 Ligase Repertoire Through Phenotypic-First Approaches”. In this presentation, RaPPIDS^TM platform will be introduced with case studies.

For more information: https://pdtueu.com/events/pdtueu

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS^TM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS^TM
RaPPIDS^TM (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS^TM platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded. 

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com